Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study

Yang, Ruocong; Líu, Hao; Bai, Chen; Wang, Yingchao; Zhang, Xiaohui; Guo, Rui; Wu, Siying; Wang, Jianxun; Leung, Elaine Lai Han; Chang, Hang; Li, Peng; Liu, Tiegang; Wang, Yi

doi:10.1016/j.phrs.2020.104820

Cited by 185 publications

(164 citation statements)

References 38 publications

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…These ingredients could suppress cytokines release, alleviate excessive immune responses and eliminate inflammation by regulating AKT1, MAPK1, MAPK3, MAPK8, MAPK14, IL-6, RELA, STAT1, JUN, and immune-related pathways, such as Th17 cell differentiation pathway, T cells, and B cells pathway, and the function of the cytokines related pathways, such as TNF signaling pathways, NF-κB, MAPK signal pathway, VEGF signaling pathways, HIF-1 signaling pathway and TLRs signaling pathways. Yang [40] also verified that the therapeutic effects of Qingfei Paidu decoction might result from glycyrrhizic acid mediated anti-inflammatory effects by suppressing IL-6 production in macrophage.…”

Section: Anti-inflammation and Immunoregulationmentioning

confidence: 88%

Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)

Huang

Bai

et al. 2020

Pharmacological Research

Self Cite

219

221

View full text Add to dashboard Cite

The Coronavirus Disease 2019 (COVID-19) has been declared as a global pandemic, but specific medicines and vaccines are still being developed. In China, interventional therapies with traditional Chinese medicine for COVID-19 have achieved significant clinical efficacies, but the underlying pharmacological mechanisms are still unclear. This article reviewed the etiology of COVID-19 and clinical efficacy. Both network pharmacological study and literature search were used to demonstrate the possible action mechanisms of Chinese medicines in treating COVID-19. We found that Chinese medicines played the role of antivirus, anti-inflammation and immunoregulation, and target organs protection in the management of COVID-19 by multiple components acting on multiple targets at multiple pathways. AEC2 and 3CL protein could be the direct targets for inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Quercetin, kaempferol, luteolin, isorhamnetin, baicalein, naringenin, and wogonin could be the main active ingredients of Chinese medicines for the management of COVID-19 by targeting on AEC2 and 3CL protein and inhibiting inflammatory mediators, regulating immunity, and eliminating free radicals through COX-2, CASP3, IL-6, MAPK1, MAPK14, MAPK8, and REAL in the signaling pathways of IL-17, arachidonic acid, HIF-1, NF-κB, Ras, and TNF. This study may provide meaningful and useful information on further research to investigate the action mechanisms of Chinese medicines against SARS-CoV-2 and also provide a basis for sharing the "China scheme" for COVID-19 treatment.

show abstract

Section: Anti-inflammation and Immunoregulationmentioning

confidence: 88%

Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)

Huang

Bai

et al. 2020

Pharmacological Research

Self Cite

219

221

View full text Add to dashboard Cite

show abstract

“…Three core CMM combinations were obtained from the data mining of the TCM formulae, in which Group 1 is MXSGD, and Group 2 and Group 3 are similar to YQP and JWQHT. Since the MXSGD plays a vital role in the treatment of COVID-19, this prescription has been extensively investigated by using the network pharmacology strategy to reveal its underlying mechanisms in the disease treatment [26] , [27] , [28] , [29] . Therefore, we explored the mechanisms of Group 2 and Group 3 prescriptions for their treatment against COVID-19.…”

Section: Resultsmentioning

confidence: 99%

Exploring the potential therapeutic effect of traditional Chinese medicine on coronavirus disease 2019 (COVID-19) through a combination of data mining and network pharmacology analysis

Sun

Jiang

Liu

2020

European Journal of Integrative Medicine

View full text Add to dashboard Cite

Introduction Historically traditional Chinese medicine (TCM) has been used as treatment during epidemics. During the recent COVID-19 pandemic patients evidence suggests that the use of TCM has provided health benefits and has been successfully used to control the spread of the disease in China. The aim of this study was to systematically explore the TCM formulae which have been used for the prevention and treatment of pneumonia or ‘pestilence’ to investigate their compatibility with the Chinese materia medica (CMM) and understand their potential mechanisms in the treatment of COVID-19. Methods Frequency analysis was performed to identify high-frequency CMM and CMM groups. Association rules analysis was applied to investigate the compatibility law of CMMs and generate the commonly used CMM groups. Results A total of 173 prescriptions were collected. The frequency analysis showed that seven out of ten high-frequency CMMs overlapped with Lianhua Qingwen Capsules (LHQWC), and five high-frequency pair-CMMs and four triple-CMMs were included in LHQWC, respectively. Then three groups of CMM were generated from association rules analysis, one of which is Ma Xing Shi Gan Decoction (MXSGD). The results of the protein-protein interaction network and enrichment analysis showed that the potential therapeutic mechanisms of the generated prescriptions were involved in the anti-inflammatory, anti-viral, and neuroprotective effects. Conclusion This study showed the importance of systematic research on TCM prescriptions and provided candidate CMM groups that have the potential to treat COVID-19. In vitro and in vivo experiments should be conducted to validate these network pharmacology results, which can provide more information for the development of potential antiviral drugs from TCM prescriptions. The combination of TCM treatment and modern medical approaches will benefit patients with COVID-19 and help to overcome the current epidemic.

show abstract

“…When compared to other research works on NP related to COVID-19 prevention and treatment, some of our research results and conclusions are consistent with the current similar research in some aspects. Qingfei Paidu Decoction (QFPD), a clinically used Chinese medicine for treating COVID-19 patients in China, has been shown by a recent NP research that the therapeutic effects of QFPD against COVID-19 may be attributed to the anti-inflammatory effects related to the thrombin and TLR signaling pathway [56]. What's more, QFPD could protect COVID-19 injury via anti-Viral, anti-Inflammatory activity and metabolic programming [57].…”

Section: Discussionmentioning

confidence: 99%

Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology

Zheng

Yan

et al. 2020

BioData Mining

View full text Add to dashboard Cite

Background Chinese medicine Xuebijing (XBJ) has proven to be effective in the treatment of mild coronavirus disease 2019 (COVID-19) cases. But the bioactive compounds and potential mechanisms of XBJ for COVID-19 prevention and treatment are unclear. This study aimed to examine the potential effector mechanisms of XBJ on COVID-19 based on network pharmacology. Methods We searched Chinese and international papers to obtain the active ingredients of XBJ. Then, we compiled COVID-19 disease targets from the GeneCards gene database and via literature searches. Next, we used the SwissTargetPrediction database to predict XBJ’s effector targets and map them to the abovementioned COVID-19 disease targets in order to obtain potential therapeutic targets of XBJ. Cytoscape software version 3.7.0 was used to construct a “XBJ active-compound-potential-effector target” network and protein-protein interaction (PPI) network, and then to carry out network topology analysis of potential targets. We used the ClueGO and CluePedia plugins in Cytoscape to conduct gene ontology (GO) biological process (BP) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis of XBJ’s effector targets. We used AutoDock vina and PyMOL software for molecular docking. Results We obtained 144 potential COVID-19 effector targets of XBJ. Fourteen of these targets-glyceraldehyde 3-phosphate dehydrogenase (GAPDH), albumin (ALB), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 1 (MAPK1), Caspase-3 (CASP3), signal transducer and activator of transcription 3 (STAT3), MAPK8, prostaglandin-endoperoxide synthase 2 (PTGS2), JUN, interleukin-2 (IL-2), estrogen receptor 1 (ESR1), and MAPK14 had degree values > 40 and therefore could be considered key targets. They participated in extracellular signal–regulated kinase 1 and 2 (ERK1, ERK2) cascade, the T-cell receptor signaling pathway, activation of MAPK activity, cellular response to lipopolysaccharide, and other inflammation- and immune-related BPs. XBJ exerted its therapeutic effects through the renin-angiotensin system (RAS), nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), MAPK, phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)-protein kinase B (Akt)-vascular endothelial growth factor (VEGF), toll-like receptor (TLR), TNF, and inflammatory-mediator regulation of transient receptor potential (TRP) signaling pathways to ultimately construct a “drug-ingredient-target-pathway” effector network. The molecular docking results showed that the core 18 effective ingredients had a docking score of less than − 4.0 with those top 10 targets. Conclusion The active ingredients of XBJ regulated different genes, acted on different pathways, and synergistically produced anti-inflammatory and immune-regulatory effects, which fully demonstrated the synergistic effects of different components on multiple targets and pathways. Our study demonstrated that key ingredients and their targets have potential binding activity, the existing studies on the pharmacological mechanisms of XBJ in the treatment of sepsis and severe pneumonia, could explain the effector mechanism of XBJ in COVID-19 treatment, and those provided a preliminary examination of the potential effector mechanism in this disease.

show abstract

Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study

Cited by 185 publications

References 38 publications

Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)

Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)

Exploring the potential therapeutic effect of traditional Chinese medicine on coronavirus disease 2019 (COVID-19) through a combination of data mining and network pharmacology analysis

Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology

Contact Info

Product

Resources

About